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COMPARISON OF TWO METHODS TO DETERMINE COSTS FOR AML 
PATIENTS IN REMISSION: MODEL VALIDATION FROM A UK 
PERSPECTIVE
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1AHRM Inc., Buffalo, NY, USA, 2AHRM Inc., Raleigh, NC, USA, 3University of Toronto, 
Toronto, ON, Canada
OBJECTIVES: To compare expected costs per AML patient in remission using deci-
sion tree and cost-in-use analysis based on a comparative 10-country phase III clinical 
trial. METHODS: Using a ﬁve-year time horizon, costs were estimated from the 
payor’s perspective for patients in their ﬁrst complete remission from AML. Clinical 
endpoints were remission (Leukemia Free), relapse and death. Resources consumed 
were taken from clinical trial data and supplemented with cost information from the 
literature and advisors (for patients in relapse). Comparators were histamine dihydro-
chloride  low dose interleukin-2 (n  129) vs. standard of care (n  132). Unit costs 
were taken from UK sources including NHS reference cost, British National Formulary 
56, National Blood Services and the literature for concomitant medications, blood 
products, emergency room visits, physician visits and relapses. Cost for interleukin 
was included; however, the investigated drug cost was not included in the analysis as 
no price has been set to date. We computed the expected cost by treatment for each 
method, using a 5% discount rate. RESULTS: Overall 5 year Leukemia Free Survival 
for treatment vs. standard of care was 2.23 years vs. 1.75 (P  0.02), respectively. 
Expected costs per treatment arm for the tree method, treatment vs standard of care, 
were £40,725 vs. £39,371, respectively, while for the cost-in-use method, treatment 
vs. standard of care was, £40,209 vs. £41,702, respectively. The tree method overes-
timated expected cost for the treatment arm by 1.3%, and underestimated the cost 
for standard of care by 5.6%. CONCLUSIONS: The two methods estimated similar 
values. However, the cost-in-use method yields a more accurate estimate compared to 
the tree method because the tree method does not adjust for events that take place 
between nodes, thus possibly introducing error. The cost-in-use method captures 
resources with known time points, minimizing over- or under-reporting of resources 
consumed.
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BACKGROUND: Mixed treatment comparisons (MTC) is useful in comparing treat-
ments when not all treatment-pairs have available head-to-head data. A previous MTC 
analysis (Dakin&James, EASL 2008) showed results that are inconsistent with 
observed data from clinical trials. We conducted analyses to understand how changing 
assumptions/implementations affect the MTC results. OBJECTIVES: To evaluate the 
performance of different MTC models in assessing the relative efﬁcacy of available 
nucleoside/tides and combinations in antiviral-naïve patients with HBeAg() CHB. 
METHODS: Proportions of HBeAg() CHB patients with undetectable HBV DNA at 
Year 1 were from published trials referenced in D&J. Bayesian MTC analyses were 
conducted using models and assumptions proposed in Higgins and Whitehead (H&W, 
1996) and Lu and Ades (L&A-Unconstrained and L&A-Constrained, 2004). Analyses 
were implemented in WinBUGS v1.4. Model performance was evaluated by how well 
it ﬁt observed proportions. RESULTS: The dataset was small relative to the number  
of comparisons evaluated. Only 10 randomized controlled trials satisﬁed D&J 
 inclusion/exclusion criteria, yielding data on only 12 of 28 possible head-to-head 
comparisons among the 8 treatments considered (LAM-lamivudine, ADV-adefovir, 
ETV-entecavir, TEL-telbivudine, TDF-tenofovir, ADVLAM, TELLAM, and PLB-
placebo). The H&W estimates were very similar to D&J results. The estimated propor-
tions from L&A-C are most consistent with observed data (see Table). Results could 
not distinguish among the four most efﬁcacious treatments at Year 1 (ETV, TDF, TEL, 
TELLAM). CONCLUSIONS: Compared with observed data, the L&A-C model is 
better able to predict observed results than either the D&J, H&W or L&A-U. With 
limited data, MTC results can vary across models and model performance should be 
evaluated against observed data. Proportion of patients achieving undetectable HBV 
DNA at Year 1: The treatments (No. Trials) for TDF(1): 74%, 75.6% (55.9%, 
91.1%), 93.7% (80.0%, 99.3%); ETV(3): 70.1% (58%-76%), 67.9% (54.8%, 
78.4%), 73.1% (57.6%, 87.6%); TEL(3): 60.1% (60%-61%), 59.1% (44.7%,71.9%),     
62.9% (44.8%,81.7%); TELLAM(1): 49%, 48.3% (25.6%,72.3%), 53.3% 
(21.9%,84.3%); ADV(4): 21.0% (13%-40%), 23.7% (14.7%,37.1%), 48.8% 
(25.8%,77.5%); LAM(6): 38.9% (32%-43%), 37.3% (26.7%,46.9%), 38.4% 
(33.9%,42.8%); ADVLAM(1): 39%, 37.9% (17.6%,61.8%), 37.5% (12.5%,68.7%); 
PLB(2): 3.7% (0%-17%), 4.7% (1.6%,9.9%), 7.1% (1.5%,18.5%) for Weighted 
Average1 (Min-Max) Observed, L&A-C Implementation2, D&J EASL20082. 1-By 
sample size; 2-Estimates (95% Bayesian Credible Interval).
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ESTIMATING THE NET HERD EFFECT INDUCED BY PCV-VACCINES: A 
HYPOTHESIS GENERATING STUDY
Sauboin C, Knerer G, Standaert B
GlaxoSmithKline Biologicals, Rixensart, Belgium
OBJECTIVES: Vaccines play an important role in the induction of herd protection. 
To date, few studies address this topic with reliable evidence. A hypothesis-generating 
modelling study of PCV-vaccine was carried out using selected variables thought to 
impact on herd effect. METHODS: A simple dynamic model was developed to 
understand potentially important factors impacting herd effect. Two patient age 
groups (0–4, 5) and 2 types of infection (i.e. vaccine and non-vaccine serotype) 
were considered. Parameters such as relative force of infection (FOI) of serotypes, 
vaccine coverage (i.e. serotype distribution and population coverage of the vaccine), 
transmission rate between age-groups and co-colonisation rate were evaluated. 
Key assumptions relate to constant birth/ death rates, serotype transmissibility, 
vaccine-induced protection duration (10y), similar transmission pattern and average 
carriage duration between vaccine serotypes and non-vaccine serotypes. RESULTS: 
Net herd effect is predicted to vary between 8% and 72% with different assumptions 
on cocolonization (factor between 0.1 and 0.7) and relative FOI for non-vaccine 
type (decreased by 1% to 10%) with a vaccine coverage of 70%. Simple intuition 
would suggest that greater vaccine coverage is associated with greater herd effect 
in the long term. However, our model suggests this occurs only when the cocoloniza-
tion of vaccine and non-vaccine serotypes represent more than 8% of the S. pneu-
moniae carriers. Therefore, the converse is actually true, i.e. more vaccine coverage 
is associated with less herd effect when cocolonization is less frequent (i.e. below 
7–8% as the literature would suggest). Demographics, contact patterns between 
individuals and the relative FOI of non vaccine serotype to vaccine serotype also 
heavily determine that effect. CONCLUSIONS: All parameters tested in our model 
impact strongly on the predicted net herd effect. Vaccine characteristics such as 
coverage are not the only and most inﬂuential factor that affects herd protection in a 
given population.
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CONTROLLING FOR UNOBSERVABLE BIAS: IS THE CURE WORSE 
THAN THE DISEASE?
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OBJECTIVES: The use of instrumental variable (IV) methods is attractive because, 
even in the presence of unmeasured confounding, such methods may consistently 
estimate the average causal effect of an exposure on an outcome. However, for this 
consistent estimation to be achieved, several strong conditions must hold. We review 
the deﬁnition of an instrumental variable, describe the conditions required to obtain 
consistent estimates of causal effects, and explore their implications in the context of 
a recent application of the instrumental variables approach. METHODS: We use two 
instrumental variables and apply Shea’s partial R-square method, the Anderson canon-
ical correlation, and Cragg-Donald tests to check for weak instruments. Hall-Pexie 
tests are applied to see if any of these instruments are redundant in the analysis. 
RESULTS: Total 15,956 asthma patients from a private payer data set were examined 
in this study. We used controller-reliever copay ratio and physician/practice prescrib-
ing patterns as an instrument. We demonstrated that the former was a weak and 
redundant instrument producing inconsistent and inefﬁcient estimates of the effect of 
treatment. The results were worse than the results from standard regression analysis. 
CONCLUSIONS: Despite the obvious beneﬁt of instrumental variable models, the 
method should not be used blindly. Several strong conditions are required for these 
models to work, and each of them should be tested. Otherwise, the results will be 
statistically worse than the results achieved by simply using standard ordinary least 
squares.
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OBJECTIVES: In the last years, the application of discrete event simulation 
(DES) increased considerably. According to a literature review, DES gives similar 
results but is much more time consuming. The objective is to compare Markov models 
and DES for chronic obstructive lung disease (COPD) using the simulation software 
ARENA. METHODS: PubMed and EMBASE were searched for articles comparing 
both approaches. Criteria were extracted to compare a Markov model for COPD 
with a DES model evolved in this study. The base COPD model is coextensive with 
a Markov model implemented in Excel, the DES model additionally incorporates 
an age distribution, which was derived from a study of the Robert Koch Institute 
(RKI). Otherwise, both models were based on the same data and probabilities. 
The models’ quality was validated by the criteria list of Philips et al. (2006) securing 
quality standards for decision analytic models. RESULTS: Comparison of both 
modeling approaches demonstrated signiﬁcant advantages of the ﬂexibility of DES. 
This was not outweighed by more complex and time consuming data evaluation, 
modeling, and simulation. DES enables more scopes for development and increasing 
modeling ﬂexibility by integrating extensions to standard Markov models. However, 
possible advantages and problems of DES were only assessed with regard to the inte-
gration of an age distribution. This distribution reﬂects the prevalence of chronic 
bronchitis and therefore differs from the real age-related prevalence of COPD. 
However, due to lacking data it was necessary to implement this distribution. CON-
CLUSIONS: DES allows modeling complex diseases with different disease stages 
and various inﬂuences. Compared to Markov models, DES is more ﬂexible in its 
application and reﬂection of reality. It provides signiﬁcant advantages in data integra-
tion and is able to gather, process, and analyze a multiple of information. The disad-
vantages of DES concerning complex data evaluation, modeling, and simulation could 
not be followed.
